Circulating microRNA 134 sheds light on the diagnosis of major depressive disorder
Open Access
- 16 March 2020
- journal article
- research article
- Published by Springer Nature in Translational Psychiatry
- Vol. 10 (1) , 1-9
Abstract
Major depressive disorder (MDD) is a prevalent and debilitating psychiatric mood disorder that lacks objective laboratory-based tests to support its diagnosis. A class of microRNAs (miRNAs) has been found to be centrally involved in regulating many molecular processes fundamental to central nervous system function. Among these miRNAs, miRNA-134 (miR-134) has been reported to be related to neurogenesis and synaptic plasticity. In this study, the hypothesis that plasma miR-134 can be used to diagnose MDD was tested. Perturbation of peripheral and central miR-134 in a depressive-like rat model was also examined. By reverse-transcription quantitative PCR, miR-134 was comparatively measured in a small set of plasma samples from MDD and healthy control (HC) subjects. To determine its diagnostic efficacy, plasma miR-134 levels were assessed in 100 MDD, 50 bipolar disorder (BD), 50 schizophrenic (SCZ), and 100 HC subjects. A chronic unpredictable mild stress (CUMS) rat model was also developed to evaluate miR-134 expression in plasma, hippocampus (HIP), prefrontal cortex (PFC), and olfactory bulb. We found that plasma miR-134 was significantly downregulated in MDD subjects. Diagnostically, plasma miR-134 levels could effectively distinguish MDD from HC with 79% sensitivity and 84% specificity, while distinguishing MDD from HC, BD, and SCZ subjects with 79% sensitivity and 76.5% specificity. Congruent with these clinical findings, CUMS significantly reduced miR-134 levels in the rat plasma, HIP, and PFC. Although limited by the relatively small sample size, these results demonstrated that plasma miR-134 displays potential ability as a biomarker for MDD.Keywords
This publication has 49 references indexed in Scilit:
- Absence of gut microbiota affects lipid metabolism in the prefrontal cortex of miceNeurological Research, 2019
- Urinary biomarker panel for diagnosing patients with depression and anxiety disordersTranslational Psychiatry, 2018
- GC-MS-based metabolomics approach to diagnose depression in hepatitis B virus-infected patients with middle or old ageAging, 2018
- Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics studyTranslational Psychiatry, 2018
- Metabolite identification in fecal microbiota transplantation mouse livers and combined proteomics with chronic unpredictive mild stress mouse liversTranslational Psychiatry, 2018
- Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolismMolecular Psychiatry, 2016
- The GABAergic deficit hypothesis of major depressive disorderMolecular Psychiatry, 2010
- Depression symptomatology and diagnosis: discordance between patients and physicians in primary care settingsBMC Family Practice, 2008
- Diagnostic categories or dimensions? A question for the Diagnostic and statistical manual of mental disorders--fifth edition.Journal of Abnormal Psychology, 2005
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005